Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 339,154	$ 438,680
Accounts receivable	2,045	1,000
Prepaid expenses and other current assets	9,022	7,965
Research and development incentives receivable	19,162	10,910
Total current assets	369,383	458,555
Property and equipment, net	19,110	3,123
Operating lease right-of-use assets	13,658	14,666
Other assets	8,458	3,448
Total assets	410,609	479,792
Current liabilities:
Accounts payable	6,472	2,721
Accrued expenses and other current liabilities	26,452	14,244
Deferred revenue, current portion	20,418	19,273
Total current liabilities	53,342	36,238
Long-term debt, net of discount	30,315	29,873
Operating lease liabilities, net of current portion	10,885	12,081
Deferred revenue, net of current portion	41,455	52,067
Other long-term liabilities	3,829	3,279
Total liabilities	139,826	133,538
Commitments and contingencies (Note 11)
Shareholders' equity:
Ordinary shares, £0.01 nominal value; 57,820,181 and 55,295,420 shares authorized at December 31, 2022 and December 31, 2021, respectively; 29,873,893 and 29,579,364 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	387	384
Additional paid-in capital	601,105	567,637
Accumulated other comprehensive income (loss)	387	(3,388)
Accumulated deficit	(331,096)	(218,379)
Total shareholders' equity	270,783	346,254
Total liabilities and shareholders' equity	$ 410,609	$ 479,792